turkey uk americas argentina brazil canada en fr colombia mexico asia pacific australia japan south korea toggle navigation search location global contact us newsroom press releases media library social media investors overview our strategy shareholder information financial highlights analyst coverage recent acquisitions baxalta dyax corp nps pharma presentations and reports presentations and webcasts quarterly results annual report 2015 annual and interim reports investor tools news events email alerts stock information newsroom press releases media library social media investors analyst coverage annual and interim reports annual report 2015 baxalta combination broker forecast email alerts events financial highlights investor news our strategy presentations and webcasts quarterly results shareholder information stock information who we are who we are our story our history our culture responsibility our approach our performance leadership board of directors executive committee how we operate partnerships policies and positions transparency disclosures partners and suppliers corporate governance patients patients patient services onepath shire cares hematology support myigsource patient advocacy about patient advocacy working together excellence in adhd patient group awards 2016 therapeutic areas adhd bleeding disorders dry eye disease gaucher disease hereditary angioedema hunter syndrome hypoparathyroidism pancreatic cancer short bowel syndrome humanitarian access improving diagnosis scholarships r & d r & d our r & d strategy research and educational grants science & innovation clinical trials pipeline collaborations products products product list manufacturing our principles product safety postmarketing commitments careers careers search & apply diversity and inclusion culture and values learning and development benefits us internship program work life balance employee profiles cuvitru receives fda approval newest addition to our ig treatment portfolio learn how cuvitru approval enhances treatment options to help physicians tailor their patients regimens . quick links partnerships patient services pipeline responsibility contact us home legal privacy policy cookies disclaimer legal notice product patents stay connected rss feed sign up for email or sms alerts website feedback shire 2016 all rights reserved cookie use notification the site uses cookies to provide you with a more responsive and personalized service . by using this site you agree to our use of cookies as set out in our cookie notice . please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies . learn more continue disagree confirm navigation by following this link you will be leaving a shire controlled website for a third party website . please note that shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences .